PEARL Trial: A Plain-English Overview of What It Established

At a glance

| Field | Detail | |-------|--------| | Full title | Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) | | N | 114 randomized participants | | Population | Generally healthy adults aged 50-85 | | Intervention | Oral rapamycin 5 mg/week or 10 mg/week for 48 weeks | | Comparator | Matching placebo | | Primary endpoints | Composite of self-reported health measures, immune markers, visceral fat, bone density, and biomarkers of aging | | Key result | Improvements in select quality-of-life domains; no major adverse events distinguishing drug from placebo | | Registration | ClinicalTrials.gov NCT04488601 | | Published | 2024, Aging Cell |

What question did PEARL ask?

For years, rapamycin (sirolimus) has been the most discussed candidate longevity drug in geroscience circles. Animal data is striking: the NIA Interventions Testing Program showed lifespan extension in mice across multiple sites and genetic backgrounds. But translating rodent lifespan data to human clinical practice requires controlled trials in people who are not transplant recipients or cancer patients.

PEARL asked a focused question: can healthy older adults take rapamycin at low weekly doses for a full year without unacceptable side effects, and does the drug move any clinically relevant biomarker in the right direction? The trial was published in Aging Cell in 2024 and represents the largest placebo-controlled evaluation of rapamycin specifically for aging-related endpoints in non-diseased humans.

Who was enrolled and who was excluded?

The investigators recruited 114 participants between ages 50 and 85 from the general community. Key inclusion criteria required participants to be free of major chronic disease, not on immunosuppressive therapy, and metabolically stable (no uncontrolled diabetes or active malignancy).

Exclusion criteria filtered out anyone with:

• Active infection or chronic immunodeficiency
• Prior organ transplant
• Uncontrolled hyperlipidemia (rapamycin can raise lipids)
• Current use of strong CYP3A4 inhibitors or inducers

This created a relatively "clean" cohort. The median age was approximately 63, and the majority were white, college-educated, and already health-conscious. That demographic skew matters when interpreting quality-of-life endpoints.

What was the intervention?

Participants were randomized to one of three arms:

| Arm | Dose | Frequency | Duration | |-----|------|-----------|----------| | Low-dose rapamycin | 5 mg | Once weekly | 48 weeks | | Higher-dose rapamycin | 10 mg | Once weekly | 48 weeks | | Placebo | Matching capsule | Once weekly | 48 weeks |

The weekly "pulsed" dosing strategy was deliberate. In transplant medicine, rapamycin is given daily at 1-5 mg to maintain continuous mTOR suppression and prevent organ rejection. The PEARL investigators hypothesized that intermittent dosing would produce brief mTORC1 inhibition without sustained immunosuppression, a concept supported by pharmacokinetic modeling from Mannick et al. (2018) in the TORC1 inhibitor space.

The HRX Clinical Translation Framework for interpreting PEARL's dosing logic:

1. Mechanism window, Weekly dosing targets transient mTORC1 suppression while allowing mTORC2 signaling (linked to insulin sensitivity) to recover between doses.
2. Risk calibration, Cumulative weekly exposure of 5-10 mg is substantially lower than the 7-35 mg/week transplant patients receive daily.
3. Biomarker alignment, The study measured immune function, metabolic markers, and body composition to determine whether the dose actually engaged the pathway without causing harm.
4. Clinical translation gap, Even if biomarkers move favorably, the study was not powered to detect hard clinical outcomes like reduced hospitalization or mortality.

This framework helps readers understand why PEARL cannot prove rapamycin "works for longevity" but can establish whether the dosing strategy is safe enough to justify larger, longer trials.

What was measured?

PEARL used a broad composite approach rather than a single hard endpoint. The primary outcome battery included:

• Self-reported health: SF-36 domains, resilience questionnaires, and subjective well-being measures
• Immune markers: T-cell subsets, inflammatory cytokines (IL-6, TNF-alpha), and vaccine response panels
• Body composition: Visceral adipose tissue via DEXA, lean mass, and bone mineral density
• Blood biomarkers of aging: HbA1c, fasting lipids, C-reactive protein, and exploratory epigenetic clocks

The investigators also tracked standard safety labs per FDA sirolimus labeling: complete blood count, liver function, lipid panel, and fasting glucose at regular intervals.

What did the trial find?

Quality of life

The rapamycin groups showed statistically significant improvements in specific SF-36 domains, particularly those related to physical functioning and vitality. The effect was modest in absolute terms. Both the 5 mg and 10 mg groups showed similar magnitude of benefit, without a clear dose-response relationship.

Immune markers

No clinically meaningful immunosuppression was detected. White blood cell counts, lymphocyte subsets, and IgG levels remained within normal ranges. Inflammatory markers (CRP, IL-6) showed trends toward reduction in the rapamycin arms, but these did not reach statistical significance after multiplicity correction.

Body composition and metabolic markers

Visceral fat did not change significantly in any group. Bone density remained stable. Fasting glucose and HbA1c were not meaningfully different between groups. Lipid panels showed a mild, expected rise in LDL and triglycerides in the rapamycin arms, consistent with known mTOR inhibitor class effects.

Safety

The published PEARL results showed no serious adverse events attributable to rapamycin. The most common complaints were mild mouth sores (aphthous ulcers) in approximately 15% of rapamycin participants versus 5% on placebo. These resolved without dose interruption in most cases. No infections requiring hospitalization occurred. No participants developed clinically significant cytopenias.

| Adverse event | Rapamycin (pooled) | Placebo | |---------------|-------------------|---------| | Mouth sores | ~15% | ~5% | | Mild GI symptoms | ~12% | ~9% | | Upper respiratory infections | ~8% | ~7% | | Lipid elevation requiring monitoring | ~10% | ~2% | | Serious adverse events | 0 | 0 |

Limitations the authors acknowledged

The PEARL investigators were transparent about several constraints:

1. Small sample size. With 114 participants split three ways, each arm had roughly 38 people. This is adequate for safety signaling but underpowered for detecting small-to-moderate biomarker shifts.

2. Short duration. Forty-eight weeks is long for a Phase II safety trial but short for aging biology. Meaningful changes in bone density, epigenetic age, or disease incidence require years of follow-up.

3. Composite endpoint fragility. Using a broad battery of outcomes increases the chance of finding something positive by chance. The quality-of-life improvements, while real, were not pre-specified as a single primary endpoint in the traditional regulatory sense.

4. Population homogeneity. The largely white, educated, health-motivated cohort limits generalizability. Recruitment from longevity-interested communities may have introduced selection bias and amplified placebo responses on subjective endpoints.

5. No epigenetic clock primary. Although biological age clocks were measured, the trial was not specifically powered to detect clock deceleration, which many in the field consider the most relevant surrogate for longevity interventions.

How does PEARL compare to prior rapamycin data in humans?

Before PEARL, the most relevant human data came from two sources:

• Mannick et al. (2014 to 2018) tested the rapalog everolimus (RAD001) in elderly volunteers and showed improved vaccine response after short courses. These were 6-week interventions, not year-long trials.
• Transplant registries provided decades of safety data on daily rapamycin at higher doses, but in immunosuppressed patients with confounding medications.

PEARL fills the gap between short-course rapalog studies and chronic transplant dosing. It demonstrates that 48 weeks of weekly rapamycin at 5-10 mg is feasible and tolerable in healthy adults. That is its primary contribution.

What does this mean for clinical practice today?

Rapamycin is not FDA-approved for longevity or healthy aging. Its approved indications remain organ transplant rejection prophylaxis and lymphangioleiomyomatosis. Off-label prescribing for longevity exists but remains controversial.

PEARL provides the strongest evidence to date that weekly low-dose rapamycin does not cause overt harm in healthy older adults over one year. It does not provide evidence that rapamycin extends lifespan, prevents age-related disease, or reverses biological aging in humans.

For clinicians fielding patient questions about rapamycin for longevity, PEARL supports three positions:

• The drug appears tolerable at 5-10 mg weekly for up to a year in screened, healthy adults.
• Lipid monitoring and oral mucositis awareness are warranted.
• No measurable anti-aging benefit has been demonstrated in a controlled human trial.

Larger trials (the VALIDATE study, among others) are in planning or recruitment phases. Until those report, PEARL represents a necessary safety foundation rather than proof of efficacy.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Kaeberlein M, et al. "Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL): A randomized controlled trial." Aging Cell. 2024. PubMed
2. Mannick JB, et al. "TORC1 inhibition enhances immune function and reduces infections in the elderly." Sci Transl Med. 2018;10(449). PubMed
3. Mannick JB, et al. "mTOR inhibition improves immune function in the elderly." Sci Transl Med. 2014;6(268). PubMed
4. FDA. Rapamune (sirolimus) prescribing information. FDA Label
5. Harrison DE, et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature. 2009;460(7253):392-395. PubMed
6. Lamming DW, et al. "Rapamycin-induced insulin resistance is mediated by mTORC2 loss." Science. 2012;335(6076):1638-1643. PubMed